TARS Tarsus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARS

Price (delayed)

$60.33

Market cap

$2.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.13

Enterprise value

$2.57B

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 45

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline ...

Highlights
Tarsus Pharmaceuticals's gross profit has soared by 130% YoY and by 19% from the previous quarter
The company's revenue has surged by 129% YoY and by 19% QoQ
The company's quick ratio fell by 35% YoY and by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tarsusrx.com
Peers: OLMA OMER

Key stats

What are the main financial stats of TARS

TARS stock price

How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
2.67%
1 week
1.33%
1 month
-6.57%
1 year
41.45%
YTD
-26.32%
QTD
-14%

Financial performance

How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$535.08M
Gross profit
$500.21M
Operating income
-$50.81M
Net income
-$48.27M
Gross margin
93.5%
Net margin
-9%
Tarsus Pharmaceuticals's gross profit has soared by 130% YoY and by 19% from the previous quarter
The company's revenue has surged by 129% YoY and by 19% QoQ
Tarsus Pharmaceuticals's net margin has surged by 80% YoY and by 39% QoQ
Tarsus Pharmaceuticals's operating margin has soared by 80% YoY and by 39% from the previous quarter

Price vs fundamentals

How does TARS's price correlate with its fundamentals

Growth

What is Tarsus Pharmaceuticals's growth rate over time

Valuation

What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.36
P/S
4.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.8
The company's EPS has surged by 58% YoY and by 29% QoQ
TARS's P/B is 63% above its 5-year quarterly average of 4.4 but 8% below its last 4 quarters average of 7.8
The company's revenue has surged by 129% YoY and by 19% QoQ
The P/S is 71% lower than the 5-year quarterly average of 16.2 and 27% lower than the last 4 quarters average of 6.5

Efficiency

How efficient is Tarsus Pharmaceuticals business performance
The company's return on sales has surged by 84% YoY and by 47% QoQ
TARS's return on invested capital has surged by 75% year-on-year and by 41% since the previous quarter
The ROA has soared by 65% YoY and by 30% from the previous quarter
TARS's ROE has soared by 64% YoY and by 28% from the previous quarter

Dividends

What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARS.

Financial health

How did Tarsus Pharmaceuticals financials performed over time
TARS's total assets is 150% greater than its total liabilities
Tarsus Pharmaceuticals's total liabilities has increased by 47% YoY and by 6% from the previous quarter
The company's quick ratio fell by 35% YoY and by 5% QoQ
Tarsus Pharmaceuticals's debt is 79% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.